Pneumonia is one of the common complications of SARS-CoV-2 infection where most patients have moderate to severe symptoms that pose a higher risk for death. This study aims to evaluate the treatment outcome of COVID-19-associated Pneumonia among patients with/without comorbidity in a public hospital in Indonesia. This is a retrospective cohort study involving unvaccinated confirmed COVID-19 patients admitted to the hospital between March and December 2020. All confirmed COVID-19 patients with Pneumonia (n = 1522) treated at the hospital were included. The majority of patients (99%) had mild COVID-19 symptoms while the remaining had moderate symptoms. The median age was about 32 years old and the average treatment duration was 6.25 ± 1.83 days. Most patients (88.8%) received a combination of azithromycin and oseltamivir. There was a very significant relationship ( p < 0.001) between comorbidities with treatment and duration of treatment of Pneumonia in COVID-19 patients. Although most patients had Pneumonia and comorbidities, they were successfully treated with azithromycin and oseltamivir combination following approximately five days of treatment.
【저자키워드】 COVID-19, Pneumonia, pre-vaccination, green zone, 【초록키워드】 Treatment, oseltamivir, Treatment outcome, SARS-COV-2 infection, hospital, Comorbidities, Comorbidity, Symptoms, Patient, Indonesia, death, Complication, moderate, COVID-19 patients, Combination, COVID-19 patient, retrospective cohort study, higher risk, median age, average, FIVE, evaluate, Most patient, treated, majority, severe symptom, mild COVID-19 symptom, 【제목키워드】 Indonesia, Public,